← Back

LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Price · split & dividend adjusted
News & notes moving LMAT
LMAT▲2

LeMaitre Vascular reports higher Q2 sales and net income, issues new guidance

LeMaitre Vascular reported second quarter 2026 sales of US$70.38 million, up from US$64.23 million a year earlier, with net income rising to US$17.05 million from US$13.78 million. Diluted earnings per share from continuing operations were US$0.74 compared with US$0.60 in the prior year period. For the first six months of 2026, sales reached US$136.93 million versus US$124.10 million, and net income was US$32.73 million against US$24.79 million. The company also issued new earnings guidance and affirmed its quarterly dividend. The results come amid a 20% share price decline over the past 30 days, with analysts estimating a fair value of US$118.75 per share, suggesting the stock is 31.4% undervalued relative to the latest close of US$81.45.
LMAT ▲
Simply Wall St·19dRead more ▾
LMAT▼

LeMaitre Vascular Shares Decline Despite Strong Earnings as Investors Take Profits

LeMaitre Vascular, Inc. reported strong first-quarter results with 10% organic revenue growth, gross margins of 72.1%, and adjusted earnings per share of $0.68, exceeding the consensus estimate of $0.66. Despite these solid fundamentals, the stock fell after the earnings release as investors took profits in one of the medical device sector's strongest performers. Prior to reporting first-quarter results on May 5, 2026, LMAT shares had appreciated approximately 38% year-to-date. Conestoga Capital Advisors, which highlighted the company in its second-quarter 2026 investor letter, continues to believe LeMaitre Vascular is well positioned for attractive revenue and earnings growth, supported by its differentiated vascular product portfolio and consistent execution.
LMAT ▼
Insider Monkey·20dRead more ▾
LMAT

LeMaitre Vascular to Report Earnings Tuesday After Market Close

Medical device company LeMaitre Vascular will announce its earnings results this Tuesday after market close. The market expects revenue to grow 11.5% year on year, a slowdown from the 15% increase recorded in the same quarter last year. Analysts have generally reconfirmed their estimates over the last 30 days, though the company has missed Wall Street revenue estimates multiple times over the past two years. LeMaitre shares are down 2.5% over the last month, heading into earnings with an average analyst price target of $118.75 compared to the current share price of $101.32.
LMAT
Yahoo Finance·23dRead more ▾
LMAT2

Surgical Equipment Stocks Post Strong Q1, Integra LifeSciences Shares Surge 64.9%

Surgical equipment and consumables specialty stocks reported a strong first quarter, with the four companies tracked by StockStory beating revenue consensus by 2.7% on average. Integra LifeSciences posted revenue of $391.9 million, up 2.4% year-on-year and 2.6% above estimates, while raising its full-year EPS guidance; its shares have surged 64.9% since the report. Intuitive Surgical delivered the biggest beat, with revenue of $2.77 billion exceeding expectations by 5.8%, though its stock fell 10.6%. Teleflex grew revenue 32.3% to $548.3 million but missed full-year EPS guidance, and LeMaitre Vascular reported $66.55 million in revenue, in line with estimates, while beating next-quarter EPS guidance.
IART ▲ISRG ▼TFX ▼LMAT
StockStory·64dRead more ▾
© 2026 MarketDXAsset